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Abstract
Dynorphin 1–17, (DYN 1–17) opioid peptide produces antinociception following binding to
the kappa-opioid peptide (KOP) receptor. Upon synthesis and release in inflamed tissues
by immune cells, DYN 1–17 undergoes rapid biotransformation and yields a unique set of
opioid and non-opioid fragments. Some of these major fragments possess a role in immuno-
modulation, suggesting that opioid-targeted therapeutics may be effective in diminishing
the severity of inflammatory disorders. This study aimed to examine the immunomodulatory
effects of DYN 1–17 and major N-terminal fragments found in the inflammatory environment
on nuclear factor-kappaB/p65 (NF-κB/p65) nuclear translocation and the release of interleu-
kin-1beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) from lipopolysaccharide (LPS)-
stimulated, differentiated THP-1 cells. The results demonstrate that NF-κB/p65 nuclear
translocation was significantly attenuated following treatment with DYN 1–17 and a specific
range of fragments, with the greatest reduction observed with DYN 1–7 at a low concentra-
tion (10 nM). Antagonism with a selective KOP receptor antagonist, ML-190, significantly
reversed the inhibitory effects of DYN 1–17, DYN 1–6, DYN 1–7 and DYN 1–9, but not other
DYN 1–17 N-terminal fragments (DYN 1–10 and 1–11) on NF-κB/p65 nuclear translocation.
DYN 1–17 and selected fragments demonstrated differential modulation on the release of
IL-1β and TNF-α with significant inhibition observed with DYN 1–7 at low concentrations
(1 nM and 10 pM). These effects were blocked by ML-190, suggesting a KOP receptor-
mediated pathway. The results demonstrate that DYN 1–17 and certain N-terminal frag-
ments, produced in an inflamed environment, play an anti-inflammatory role by inhibiting
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NF-κB/p65 translocation and the subsequent cytokine release through KOP receptor-
dependent and independent pathways.
Introduction
Dynorphin 1–17 (DYN 1–17) opioid peptide is endogenously released from immunocytes and
neurons upon enzymatic cleavage of the precursor prodynorphin molecule, yielding a
17-amino acid sequence. It selectively binds to the kappa-opioid receptor (KOP receptor) and
may also interact with delta-opioid receptor (DOP receptor) and to a lesser extent at mu-opioid
receptor (MOP receptor) [1–3]. Similarly to other endogenous opioids, DYN 1–17 is suscepti-
ble to rapid enzymatic degradation, generating a variety of smaller fragments representing a
number of cleavage points [4]. Our laboratory has previously demonstrated that DYN 1–17 is
biotransformed in rat inflamed tissue to a unique array of opioid and non-opioid fragments,
different to those seen within non-inflamed tissue or blood at acidic pH, reflecting the naturally
occurring inflammatory environment [5]. In addition to its analgesic effect, evidence has also
reported the involvement of DYN 1–17 and its major biotransformation fragments in the regu-
latory control of both cellular and humoral immune responses [6, 7] including enhancement of
the tumouricidal activity of murine macrophages upon stimulation by lipopolysaccharide
(LPS) and interferon-gamma (IFN-γ) [8], zymosan-mediated oxidative burst in the macro-
phage cell line J774 [9] and suppression of the natural killer cell and antigen-specific cytolytic
T cell activity [10]. The underlying signal transduction mechanisms required for these activi-
ties, however, remain poorly understood.
The nuclear factor-kappa B (NF-κB) signalling pathway is one of the possible mechanisms
that mediates the immunomodulatory roles of opioids in inflammation and is central to the
pathogenesis of a range of chronic inflammatory-related diseases [11]. Under resting cell con-
ditions, inactive, cytoplasmic NF-κB is bound to its inhibitor proteins, the IκBs. Activation of
IκB kinase (IKK) complexes by pro-inflammatory cytokines e.g. tumor necrosis factor-alpha
(TNF-α) or LPS leads to phosphorylation of IκB and proteasome degradation, releasing active
NF-κB complexes in the cytoplasm. Activated NF-κB complexes translocate to the nucleus,
then bind to the DNA promoter region followed by transcription and expression of various
inflammatory mediators such as cytokines, chemokines, and endothelial cell adhesion mole-
cules [12, 13]. Activation of the NF-κB signalling pathway provides a positive autoregulatory
loop in synchronizing and maintaining immune response towards infection or painful stimuli
[14]. For instance, NF-κB activation of the innate immune system triggers the release of pro-
inflammatory cytokines and subsequently these mediators further promote the infiltration and
migration of immunocytes in the adaptive immune system to coordinate the inflammatory
response to produce pain signals [15]. The MOP receptor agonist, morphine, has been reported
to have differential modulation on LPS-induced activation of NF-κB and downstream release
of TNF-α and IL-6 in macrophages, depending on the morphine concentrations [16] whereas
in another study, this opioid peptide was found to inhibit NF-κB translocation in T cells. The
discrepancy might be due to that the MOP receptor is coupled to different second messenger
systems in different cell types, causing cell type-specific effects of the morphine [17]. These
findings, however, suggest an association between opioids and NF-κB pathway in modulating
the severity of inflammatory disorders. In this study, we examine the immunomodulatory
effects of DYN 1–17 and major N-terminal fragments observed in the inflammatory environ-
ment, on LPS-stimulated NF-κB/p65 nuclear translocation and downstream release of
DYN 1-17, NF-kappa B, Interleukin-1beta and TNF-alpha
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inflammatory cytokines (IL-1β and TNF-α) in THP-1 cells and elucidate the involvement of
the KOP receptor in this pathway. Our results reveal a potential role for DYN 1–17 biotrans-
formed fragments in mediating inflammatory signals in macrophages through KOP receptor
pathways.
Materials and Methods
Reagents
DYN 1–17, and a range of N-terminal fragments (DYN 1–6, DYN 1–7, DYN 1–9, DYN 1–10
and DYN 1–11) were supplied by Mimotopes Pty. Ltd, Australia. Purity was greater than 95%
for all peptides. LPS from Escherichia coli, serotype O55:B5 was purchased from Enzo Life Sci-
ences (Farmingdale, NY, USA), phorbol 12-myristate 13-acetate (PMA) was purchased from
Adipogen (San Diego, CA, USA) and 4',6-diamidino-2-phenylindole (DAPI) was purchased
from Cayman Chemical (MI, USA). Primary rabbit monoclonal anti-NF-κB/p65 [E379] anti-
body (ab32536), goat anti-rabbit IgG H&L (Alexa Fluor 555; ab150078) and goat anti-mouse
IgG H&L (Alexa Fluor 647; ab150115) were provided by Abcam (Cambridge, MA, USA). The
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reagent, dimethyl
sulfoxide (DMSO), IMD-0354 and foetal bovine serum (FBS) were purchased from Sigma
Aldrich (St Louis, MO, USA) whereas penicillin-streptomycin (Pen-Strep) solution and RPMI
1640 medium were supplied by Life Technologies (VIC, Australia). Primary mouse monoclo-
nal KOP receptor antibody was obtained from Life Research Pty. Ltd., Australia.
Cell culture and differentiation
The human monocytic cell line, THP-1 (ATCC No TIB-202) cells were grown in suspension
for up to 30 passages and maintained in culture medium containing RPMI 1640 supplemented
with 10% FBS, 2 mM L-glutamine, 2 g/L D-glucose and 1% Pen-Strep in a humidified atmo-
sphere of 5% CO2 at 37°C [18, 19]. The induction of THP-1 cells into mature macrophage-like
state was achieved in all experiments by re-suspending the cells in culture medium containing
PMA (50 nM), for 48 hr. Stimulation with PMA has been shown to induce the differentiation
of THP-1 cells into functional macrophages [20].
Assessment of THP-1 cells viability
The viability of THP-1 cells was determined by performing an MTT assay as described previ-
ously [21, 22]. Briefly, PMA-induced THP-1 cells were seeded in 24 well plates (5 x 105 cells/
well) and cultured in 1 mL of culture medium containing DYN 1–17 and selected fragments at
different concentration (10 nM and 1 μM) for 24 hr at 37°C under 5% CO2. Cells incubated
with culture medium alone served as the positive control for this assay. MTT reagent (220 μL/
well) was then added to the cell cultures to reach a final concentration of 2.5 mg/mL and incu-
bated for an additional 2 hr at 37°C. The dark crystals formed were dissolved by adding DMSO
(1200 μL) into each well at 37°C. Subsequently, the plate was incubated with gentle continuous
agitation for 20 minutes on an orbital shaker (Ratek Instruments, VIC, Australia). Aliquots
(100 μL) from each well were then transferred in duplicate into a 96-well plate. Wells contain-
ing DMSO only in equivalent volume were used as blank. The optical density of the produced
intracellular formazan, proportional to the number of viable cells present, was measured by
using a microplate reader (Bio-Rad Laboratories, CA, USA) at 590 nm. The average viable cell
value after blank absorbance subtraction was calculated as a fraction of the average value
obtained from cells incubated with medium alone.
DYN 1-17, NF-kappa B, Interleukin-1beta and TNF-alpha
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Assessment of LPS-stimulated NF-κB/p65 translocation in differentiated
THP-1 cells
Cells were seeded in 96-well black microplates at a density of 1.5 x 105cells (150 μL/well) and
induced by PMA (50 nM) for 48 hr followed by a 24-hour incubation in PMA-free culture
medium. After differentiation into macrophages, cells were serum-starved in 2% FBS-contain-
ing RPMI 1640 medium for 15 hr before the medium was discarded. LPS (1 μg/mL) was used
to stimulate the differentiated THP-1 cells whereas non-stimulated cells received an equivalent
volume of the media, serving as the negative control. To check the functionality of our NF-κB/
p65 translocation assay, a synthetic selective NF-κB inhibitor, IMD-0354 (10 μM; Sigma-
Aldrich, MO, USA) was used to treat both LPS- and non-stimulated cells for an hour in a con-
stant environment of 5% CO2 at 37°C. The corresponding DMSO concentration (0.1% v/v)
was similarly prepared as a diluent control for IMD-0354.
Treatment of DYN 1–17 and selected fragments
Differentiated THP-1 cells (1.5 x 105cells) were stimulated with LPS as previously described in
the presence of DYN 1–17 and other fragments at two different concentrations (10 nM and
1 μM) for an hour in a humidified atmosphere at 37°C and 5% CO2. Different concentrations
of the DYN 1–17 and the fragments were prepared by diluting the stock solutions in RPMI
1640 supplemented with 10% FBS. LPS-stimulated and non-stimulated groups were prepared
as described previously. The KOP receptor activities of DYN 1–17 and other fragments on NF-
κB/p65 translocation were determined using ML-190, a selective KOP receptor antagonist. The
cells were pre-treated with ML-190 (1 μM) for an hour followed by co-treatment with DYN
1–17 fragments (10 nM) and ML-190 (1 μM) for an additional hour at 37°C under 5% CO2.
Co-treatment of IMD-0354 (10 μM) and ML-190 (1 μM) was also performed separately to con-
firm that there was no cross-activity between both drugs. A corresponding DMSO concentra-
tion (0.1% v/v) was similarly prepared as a diluent control for both IMD-0354 and ML-190.
Assessment of NF-κB/p65 translocation and image analysis
Differentiated THP-1 cells receiving treatment, both non-stimulated and LPS-stimulated were
fixed with freshly prepared cold formaldehyde (3.7%) for 15 minutes and then rinsed three
times with PBS before adding blocking buffer (containing 5% normal goat serum and 0.3% Tri-
ton X-100) for an hour at room temperature to allow cell permeabilisation and to block non-
specific protein-protein interactions. Primary anti-NF-κB/p65 rabbit monoclonal antibody
(1:400) was then added into each well and incubated overnight at 4°C. Next, the cells were
incubated with secondary Alexa Fluor1 555 goat anti-rabbit IgG (H+L) polyclonal antibody
(1:500) for 2 hr followed by DAPI (2 μg/mL) staining for nucleic acid detection for 10 minutes
at room temperature under subdued laboratory lighting. Cells were washed with PBS in tripli-
cates between the incubations. The experimental plates were imaged using the ImageXpress
Micro high content screening imaging system (Molecular Devices, Sunnyvale, CA). Four fields
of view (2000 pixel × 2000 pixel each) were captured from each well with a 10x-magnifiying
lens. Images were analyzed using customised colocalisation algorithms provided in the Meta-
morph software. NF-κB/p65 immunofluorescence derived from the images at the nuclear level,
as identified by DAPI staining, was evaluated as positive DAPI overlapping pixels. The number
of overlapping pixels in NF-κB/p65 (green) images and DAPI (blue) images from each cellular
nuclear area obtained from multiple images were determined and logged into an Excel spread-
sheet. Observation for the subcellular localization of NF-κB/p65 in THP-1 cells was performed
similarly as described previously with the exception that a special 96-well optics black plate
DYN 1-17, NF-kappa B, Interleukin-1beta and TNF-alpha
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with clear bottom polystyrene (Corning) was used. Cells were imaged on Nikon Eclipse Ti
inverted microscope through an ×63 oil immersion objective lens (1.4 NA; PlanApo, Nikon)
equipped with a 12-bit Coolsnap HQ cooled CCD camera (Roper Scientific). In addition to
this, the expression of KOP receptor in differentiated THP-1 cells was also observed using a
similar method as described above with the exception that mouse kappa opioid receptor mono-
clonal antibody (30 μg/mL) and secondary Alexa Fluor1 647 goat anti-mouse IgG (H+L) poly-
clonal antibody (1:300) were used. The images of KOP receptor expression were observed
using an inverted microscope at 20x magnification. The specificity of monoclonal KOP recep-
tor used in the study was verified previously, showing no specific staining pattern in the
absence of primary antibody.
Human IL-1β and TNF-α bioassay
Differentiated THP-1 cells were seeded in 96-well microplates at a density of 4 x 105cells/well
and stimulated with LPS (1 μg/mL) (200 μL/well) to release IL-1β and TNF-α followed by incu-
bation with DYN 1–17 and other fragments at different concentrations (0.1 μM, 1 nM and 10
pM) within a humidified atmosphere at 37°C and 5% CO2. Culture supernatants were collected
after 24 hr of treatment period and added to a 384-well plate (1 μL/well) in duplicate. The level
of human IL-1β and TNF-α secretion was quantified using AlphaLISA kit (Perkin Elmer, VIC,
Australia) according to the manufacturer’s protocol. In brief, anti-IL-1β or anti-TNF-α conju-
gated to acceptor beads and biotinylated antibody were added into each well followed by one
hour incubation at room temperature under subdued lighting. To detect the assay signal, strep-
tavidin donor beads were added and the plate was incubated for 30 minutes at room tempera-
ture. The AlphaLISA signal was then read using an Enspire-Alpha 2390 Multilabel Plate
Reader.
Statistical analysis
All experiments were performed in triplicates and the data presented as the mean ± standard
error of the mean (S.E.M.) from at least three independent experiments. Data calculations and
comparisons between the groups were analysed with GraphPad Prism software (Version 6.07)
using one-way ANOVA followed by post-hoc Bonferroni test. A significant difference between
groups was defined as p 0.05.
Results
LPS stimulated the nuclear localization of NF-κB/p65 in differentiated
THP-1 cells
The LPS-mediated NF-κB/p65 translocation in differentiated macrophages was observed qual-
itatively upon immunolabelling of differentiated THP-1 cells with NF-κB/p65 primary anti-
body and detected by Alexa Fluor1 555 goat anti-rabbit IgG using TRITC filter and a 63×
objective. The p65 subunit of NF-κB (green) was present predominantly in the cytoplasm of
non-stimulated macrophages (Fig 1A). LPS stimulation resulted in strong nuclear labelling of
NF-κB/p65 in stimulated cells (Fig 1B), reflecting the translocation of cytosolic NF-κB/p65
protein into the nuclei (blue). This result confirmed that LPS stimulation resulted in NF-κB/
p65 translocation in PMA-differentiated THP-1 cells.
DYN 1-17, NF-kappa B, Interleukin-1beta and TNF-alpha
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DYN 1–17 and the N-terminal fragments inhibited NF-κB/p65 nuclear
translocation in LPS-stimulated THP-1 cells
The ability of DYN 1–17 and its N-terminal fragments to inhibit the NF-κB/p65 nuclear trans-
location index in differentiated THP-1 cells was measured quantitatively using a high content
screening approach. As shown in Fig 2, LPS induced greater than 50% of the NF-κB/p65 trans-
location in differentiated cells in comparison with the non-stimulated cells. Upon adding DYN
1–17 and the N-terminal fragments (DYN 1–6, 1–7, 1–9, 1–10, 1–11), NF-κB/p65 nuclear
translocation was significantly inhibited between 20–40% at both high and low concentrations
(1 μM and 10 nM, respectively) when compared to the LPS positive control group (p0.05).
This inhibitory effect was also observed in LPS-stimulated cells treated with U50,488H (1 μM
and 10 nM), a selective KOP receptor agonist (p0.05). Amongst these fragments, DYN 1–7
at 10 nM inhibited NF-κB/p65 translocation to the greatest extent, with around 44% inhibition
relative to the LPS control group. This finding indicates that DYN 1–17 and the N-terminal
DYN 1–17 fragments are involved in the attenuation of NF-κB/p65 nuclear translocation in
LPS-stimulated THP-1 cells.
DYN 1–17 and the N-terminal fragments, however, had no effect on NF-κB/p65 nuclear
translocation in non-stimulated cells (S1 Fig). In addition, the MTT assay revealed that none of
the N-terminal fragments of DYN 1–17 had any significant effect on the viability of THP-1
cells at both 10 nM and 1 μM in comparison with the relevant control group (S2 Fig). This
finding therefore excludes non-specific cytotoxicity as a possible explanation for NF-κB/p65
inhibition. The differentiated THP-1 cells treated with LPS were also treated with IMD-0354, a
Fig 1. NF-κB/p65 nuclear localisation in differentiated THP-1 cells.Cells were fixed, permeabilised, stained with anti-NF-κB/p65 rabbit monoclonal
antibody and visualised with Alexa Fluor1 555 goat anti-rabbit IgG (green). The nuclei were counterstained with DAPI (blue). Microscopy imagesA. Inactive
NF-κB/p65 proteins localisation in the cytoplasm of the non-stimulated THP-1 cells (top row) andB. Translocated NF-κB/p65 proteins into the nuclei of THP-1
cells following LPS stimulation (bottom row). Images were acquired for each fluorescence channel, using suitable TRITC and DAPI filters and a 63×
objective. Scale bar: 10μm
doi:10.1371/journal.pone.0153005.g001
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selective IKK-2 inhibitor in order to check the functionality of our NF-κB/p65 nuclear translo-
cation assay. IMD-0354 acts by blocking IKBα phosphorylation and thus prevents the induc-
tion of NF-κB/p65 nuclear translocation [23]. As shown in Fig 3, IMD-0354 produced a
significant reduction in NF-κB/p65 translocation in comparison with the control group
(DMSO 0.1% v/v as diluent control) (p0.05). No significant difference for NF-κB/p65
nuclear translocation was observed in non-stimulated THP-1 cells treated with IMD-0354.
The expression of KOP receptor in LPS-stimulated THP-1 cells
DYN 1–17 has been reported to act primarily at the KOP receptor. As shown in Fig 4, the pres-
ence of KOP receptor expression was visualised on the cell surface of the LPS-stimulated differ-
entiated THP-1 cells upon immunolabelling with a monoclonal antibody to KOP receptor.
This observation further confirmed that membrane-bound KOP receptor is endogenously
expressed in differentiated THP-1 cells.
The involvement of KOP receptor in mediating the inhibitory effects of
DYN 1–17 and the N-terminal fragments on NF-κB/p65 nuclear
translocation in LPS-stimulated THP-1 cells
DYN 1–17 and U50,488H are KOP receptor agonists. To further investigate the involvement
of KOP receptor in the attenuation of activated NF-κB/p65 translocation into the nucleus by
Fig 2. The attenuation of NF-κB/p65 nuclear translocation by DYN 1–17 and the N-terminal fragments in LPS-stimulated THP-1 cells. The LPS-
stimulated THP-1 cells were treated with the N-terminal fragments of DYN 1–17 and U50,488H at 1 μM and 10 nM for an hour. The treated cells were fixed
with paraformaldehyde (3.7%) and immunolabelled with primary anti-NF-κB/p65 monoclonal antibody and visualized using Alexa Fluor 5551 secondary
antibody. DAPI staining was used to identify the nuclei. The nuclear translocation of NF-κB/p65 in each treatment group was assessed using the Image
Xpress screening system. Non-stimulated THP-1 cells (NS) served as negative control. The NF-κB/p65 translocation percentage in each treatment group
was normalised and expressed relative to LPS-stimulated control group. Data shown are the means ± S.E.M. of at least three independent experiments
performed in triplicates, *p 0.05.
doi:10.1371/journal.pone.0153005.g002
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the major biotransformation N-terminal fragments of DYN 1–17 and U50,488H (as a positive
control), differentiated THP-1 cells were pre-treated with ML-190 (1 μM) followed by co-treat-
ment of DYN 1–17 and other fragments (10 nM) or U50,488H (10 nM) with ML-190 (1 μM)
in LPS-stimulated cells. DMSO 0.1% v/v served as the diluent control for ML-190. As shown in
Fig 5, the inhibitory effects of DYN 1–17, DYN 1–6, DYN 1–7, DYN 1–9 and U50,488H on
NF-κB/p65 nuclear translocation in LPS-stimulated cells were significantly reversed upon
addition of ML-190 (p0.05). However, no reversal effect was observed when ML-190 was co-
treated with other N-terminal fragments (DYN 1–10 and DYN 1–11). Both LPS-activated cells
treated with either DMSO or ML-190 alone exhibited similar activity on nuclear translocation
as compared to the LPS-stimulated group (Fig 5). The results suggest that the inhibition of NF-
κB/p65 nuclear translocation by DYN 1–17, DYN 1–6, DYN 1–7 and DYN 1–9 is mediated by
the KOP receptor. The role of the KOP receptor was confirmed following ML-190 blockade of
U50,488H mediated inhibition of NF-κB/p65 nuclear translocation (Fig 5).
Fig 3. Effect of IMD-0354 on the NF-κB/p65 nuclear translocation in LPS-stimulated THP-1 cells. The
LPS-stimulated THP-1 cells were treated with IMD-0354 (10 μM) and DMSO (0.1% v/v, as diluent control).
The treated cells were fixed with paraformaldehyde (3.7%) and immunolabelled with primary anti-NF-κB/p65
rabbit monoclonal antibody and visualized using Alexa Fluor 5551 secondary antibody. DAPI staining was
used to identify the nuclei. The nuclear translocation of NF-κB/p65 in each treatment group was assessed
using the Image Xpress system. Non-stimulated THP-1 cells (NS), receiving similar treatment served as
negative control. The percentage of NF-κB/p65 nuclear translocation in each treatment group was
normalised and expressed relative to LPS-stimulated control group. Data represents means ± S.E.M. of at
least three independent experiments performed in triplicates, *p 0.05.
doi:10.1371/journal.pone.0153005.g003
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The effects of DYN 1–17 and the N-terminal fragments on the LPS-
stimulated release of human IL-1β and TNF-α in differentiated THP-1
cells
In this study, the effect of DYN 1–17 and the N-terminal fragments (DYN 1–6, 1–7, 1–9, 1–10
and 1–11) on LPS-stimulated release of IL-1β and TNF-α was investigated at concentrations of
0.1 μM, 1 nM and 10 pM. LPS induced a significant increase of IL-1β and TNF-α levels at 24
hr, indicating that LPS activated THP-1 cells to release IL-1β and TNF-α in comparison with
the non-stimulated cells (Fig 6). Treatment with DYN 1–17 resulted in a reduction of IL-1β
release in a concentration-independent manner as compared to the LPS control group but no
significant modulation on TNF-α release was observed (Fig 6A). Interestingly, DYN 1–7 signif-
icantly decreased the levels of both cytokines, with a 15–30% reduction in a concentration-
dependent manner (p0.05) when compared with LPS control group (Fig 6C). In contrast,
administration of DYN 1–6 significantly augmented the release of IL-1β (at 0.1 μM, 1 nM and
10 pM) and TNF-α (at 0.1 μM and 1 nM) around 10–20% in comparison to LPS control group
(Fig 6B). It is of note, however, that incubation with DYN 1–9, DYN 1–10 and DYN 1–11 did
not have any significant modulation on the release of both IL-1β and TNF-α levels in LPS-
stimulated THP-1 cells (S4 Fig). At 10 pM, the selective KOP receptor agonist, U50,488H
inhibited the release of both IL-1β and TNF-α (Fig 6D) around 20% of the LPS control group
(p0.05).
To determine whether the changes to IL-1β and TNF-α release seen with the DYN frag-
ments were mediated by the KOP receptor, ML-190 was used to block KOP receptor activity.
Incubation with ML-190 (10 μM) alone did not significantly affect the LPS-stimulated IL-1β
and TNF-α release in differentiated THP-1 cells (S3 Fig). Treatment with ML-190 significantly
blocked the effects of DYN 1–17 (Fig 6A) and DYN 1–6 (Fig 6B) by 15–20% on the LPS-
induced IL-1β release at 0.1 μM and 1 nM, respectively (p0.05). Interestingly, ML-190 also
partially reversed the inhibition of IL-1β release by DYN 1–7 (Fig 6C) and U50,488H (Fig 6D)
at 10 pM (p0.05). However, no reversal effect by ML-190 was found following modulation of
DYN 1–17, DYN 1–6 and DYN 1–7 at other concentrations on LPS-stimulated IL-1β release.
Further observations demonstrated that ML-190 blocked the augmentation of TNF-α release
by DYN 1–6 (0.1 μM) (Fig 6B). Consistent with the IL-1β data, the inhibition of TNF-α release
Fig 4. The expression of KOP receptor on LPS-stimulated THP-1 cells. Cells were fixed, permeabilised, immunolabelled with KOP receptor monoclonal
antibody and visualised with Alexa Fluor 6471 goat anti-mouse IgG (red). The nuclei were counterstained with DAPI (blue). Images were acquired for each
fluorescence channel, using suitable FITC and DAPI filters with 20 × objective. Scale bar: 25μm
doi:10.1371/journal.pone.0153005.g004
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by DYN 1–7 (Fig 6C) and U50,488H (Fig 6D) at 10 pM was also significantly blocked by ML-
190. Additionally, ML-190 reversed the inhibition of TNF-α by DYN 1–7 at 1 nM (Fig 6C).
Overall findings on the effects on DYN 1–17 and its N-terminal biotransformation frag-
ments on NF-κB/p65 nuclear translocation and pro-inflammatory cytokine release were sum-
marised in Table 1.
Discussion
The NF-κB transcription factor is essential in regulating various inflammatory-related genes.
Upon stimulation by LPS on the differentiated THP-1 cells, downstream activation of the NF-
Fig 5. Effect of ML-190 on the attenuation of NF-κB/p65 nuclear translocation by DYN 1–17 and the N-terminal fragments in LPS-stimulated THP-1
cells. The LPS-stimulated THP-1 cells were pre-treated with ML-190, a KOP receptor antagonist (1 μM, 1 hour) followed by co-treatment of the DYN 1–17
and the N-terminal fragments (10 nM) or U50,488H (10 nM) with ML-190 (1 μM, 1 hour). The treated cells were fixed with paraformaldehyde (3.7%) and
immunolabelled with primary anti-NF-κB/p65 rabbit monoclonal antibody and visualized using Alexa Fluor 5551 secondary antibody. DAPI staining was
used to identify the nuclei. The nuclear translocation of NF-κB/p65 in each treatment group was assessed using the Image Xpress system. Non-stimulated
THP-1 cells (NS) served as negative control. The percentage of NF-κB/p65 nuclear translocation in each treatment group was normalised and expressed
relative to LPS-stimulated control group (contains DMSO 0.1% as diluent control). Data shown are the means ± S.E.M. of at least three independent
experiments performed in triplicates, *p 0.05.
doi:10.1371/journal.pone.0153005.g005
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κB signalling pathway is triggered, leading to the production of various inflammatory cytokines
such as IL-1β and TNF-α at the gene level [24]. Among the NF-κB transcription factor family
of proteins, the most abundant complex found in mammalian species is the heterodimeric
p65-p50. The p50 subunit has been suggested as a helper in DNA binding whereas the p65 sub-
unit possesses a more important role as the activator of the transcriptional activity of NF-κB
complex [25]. The NF-κB/p65 nuclear translocation assay performed in this study allows
quantitative measurement on the degree of the translocation, hence enabling investigation of
pharmacological modulation. This assay measures NF-κB/p65 redistribution from the cyto-
plasm to the nucleus and indirectly quantifies IκB degradation [26].
In the present study, the greatest inhibitory effect on NF-κB/p65 translocation was seen
with DYN 1–7 at 10 nM, reducing translocation two-fold in comparison with the LPS control
group. Other N-terminal fragments of DYN 1–17 elicited an inhibitory effect on NF-κB/p65
Fig 6. Themodulation of DYN 1–17 and the N-terminal fragments on the release of IL-1β and TNF-α in LPS-stimulated THP-1 cells. The LPS-
stimulated THP-1 cells were treated with the N-terminal fragments of DYN 1–17 and U50,488H at 0.1 μM, 1 nM and 10 pM for 24 hr. The culture supernatants
were collected and IL-1β and TNF-α release was measured using IL-1β and TNF-α AlphaLISA kit, respectively. The AlphaLISA signal was read using an
Enspire-Alpha 2390 Multilabel Plate Reader. Non-stimulated THP-1 cells (NS) served as negative control. The release of IL-1β and TNF-α in each treatment
group was normalised and expressed relative to LPS-stimulated control group. Data shown are the means ± S.E.M. of at least three independent
experiments performed in triplicates. Statistical significance as denoted by * and # represent the IL-1β and TNF-α release between peptide-treated (solid-
line) and LPS-stimulated control group or ML-190-treated group (dotted-line), respectively, p 0.05.
doi:10.1371/journal.pone.0153005.g006
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nuclear translocation at 1 μM and 10 nM, suggesting that these biotransformation fragments
possess a potential immunomodulatory function during inflammation. Supporting this notion,
N-terminal fragments of DYN 1–17 have been shown previously to modulate phagocytosis
and tumouricidal activity in mouse [8, 27]. Notwithstanding that the affinity of opioid peptides
for the opioid receptor is in the nanomolar range [16], the differential effects seen with concen-
tration dependency can potentially be explained through the outcome of effects on multiple
different mechanisms, with combined effects of the same signals.
Previous reports have also described that cytokine release is a consequence of extensive reg-
ulation of NF-κB transcription and translation processes [13, 28]. In this study, DYN 1–17 and
select N-terminal biotransformation fragments (DYN 1–7 and DYN 1–6) modulated the
release of IL-1β and TNF-α with the greatest reduction of both cytokines levels being observed
following treatment with DYN 1–7 at low concentrations. The maximal inhibition of NF-κB/
p65 translocation by DYN 1–7, which was around 40%, correlated with a 15–30% inhibition of
IL-1β and TNF-α release. These findings are consistent with the modulation of NO and TNF-α
release observed for DYN 1–17 and DYN 1–8 in mixed glia cells at subnanomolar concentra-
tions [29]. It has also been reported that U50,488H at 0.1 nM suppressed the release of IL-1
and TNF-α in LPS-induced P388D1 macrophages, while at higher concentrations the effect
was reduced [30]. Surprisingly, DYN 1–6 increased the release of both IL-1β and TNF-α
whereas DYN 1–17 only modulated IL-1β and not TNF-α release, suggesting differential effects
of these biotransformation fragments on cytokine modulation.
DYN 1–17 has been shown to bind to both opioid and non-opioid receptors [31, 32]. Many
studies attribute the effects of DYN 1–17 largely to activity at the KOP receptor [33, 34]. Evi-
dence indicates that the KOP receptor is expressed in cell lines of both neural and non-neural
origin [35]. KOP receptor mRNA expression has been reported in THP-1 cells [36] and here
we have verified the expression of the KOP receptor on the cell surface of LPS-induced differ-
entiated THP-1 cells in this study. Up-regulation of KOP receptor expression concurrently
with the release of DYN 1–17 in inflamed tissue has also been reported, indicating that inflam-
mation directly influences opioid-mediated peripheral analgesia [37, 38].
The KOP receptor has also been demonstrated to mediate immune system function [39]. To
determine whether the effect of selected fragments of DYN 1–17 on NF-κB/p65 translocation
was mediated by KOP receptor, the selective KOP receptor antagonist, ML-190 was used.
Table 1. The Effects of DYN 1–17 and Its N-terminal Biotransformation Fragments on LPS-stimulated
NF-κB/p65 nuclear translocation.
Treatment Inhibition of NF-
κB/p65 nuclear
translocation
Modulation of IL-1β release Modulation of TNF-α release
10 nM 1 μM 10 pM 1 nM 0.1 μM 10 pM 1 nM 0.1 μM
DYN 1–17
p
*
p # # #* $ $ $
DYN 1–6
p
*
p " "* " $ " "*
DYN 1–7
p
* X #* # # #* #* #
DYN 1–9
p
*
p $ $ $ $ $ $
DYN 1–10
p p $ $ $ $ $ $
DYN 1–11
p p $ $ $ $ $ $
U50,488H
p
* X #* $ $ #* $ $
*significant antagonism with ML-190, p  0.05
# = inhibit, " = enhance,$ = no changes, p = yes, X = no
doi:10.1371/journal.pone.0153005.t001
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ML-190 is a newly discovered antagonist for KOP receptor that elicits much higher KOP recep-
tor potency (IC50 = 120 nM in β-arrestin assay) over MOP and DOP receptors. In comparison
with other selective KOP receptor antagonists such as GNTI, norBNI and JDTic, ML-190 pos-
sesses a promising potency and an improved selectivity for the KOP receptor (> 267-fold selec-
tive over that of MOP and DOP receptors) with a slightly cleaner binding profiles, making this
drug suitable for studying KOP receptor distribution and internalisation [40]. Furthermore,
ML-190 has a simplified structures that contains no stereochemical centres, highly modular
and achiral compared to the other currently available KOP receptor antagonist with better sol-
ubility profile across the pH range tested. This antagonist is also readily synthesised following
screening over a group of hit compounds due to its short and versatile synthetic route which
allows the production of this compound on larger scale [41].
ML-190 significantly reversed the inhibitory effect of DYN 1–17 and N-terminal fragments
(DYN 1–7, DYN 1–6 and DYN 1–9) on NF-κB/p65 translocation along with the KOP receptor
selective agonist, U50,488H. This demonstrated that DYN 1–17 and N-terminal fragments
(DYN 1–7, DYN 1–6 and DYN 1–9) suppress the translocation of cytosolic NF-κB/p65 protein
into the nuclei of THP-1 cells through activation of KOP receptors. Consistent with our find-
ings, activation of the KOP receptor in immune cells by DYN 1–17 and other derivatives nega-
tively regulate the antigen-induced proliferation of T cells [42], antibody production by B
cells [43], phagocytic ability [44] and also cytokine production by macrophages [45]. Further-
more, anti-tumour activity in peritoneal macrophages has been reported for DYN 1–17 and
several N-terminal sub-fragments at KOP receptors [8, 46]. On the contrary, it was previously
reported that DYN 1–17 and related fragments promote peritoneal macrophage phagocytosis,
however this enhancement was not reversed by naloxone, suggesting that this immunomodula-
tion is mediated via non-opioid receptors [27]. Furthermore, the difference of the methods and
receptors used by Szabo et al. [44] and Ichinose et al. [27] for phagocytosis assay may explain
the distinct responses of DYN 1–17 towards the phagocytic activity in mouse peritoneal
macrophages.
The inhibition of NF-κB/p65 translocation by other longer N-terminal fragments (DYN
1–10 and DYN 1–11), however, was not reversed by ML-190; suggesting that, in this instance,
the inhibitory effect of these fragments on NF-κB/p65 translocation could be mediated by
other opioid receptors or by non-opioid receptors. The presence of a tyrosine residue on the
first position of the amino acid chain allows binding between opioid peptides (except for
orphanin) and their specific opioid receptors. Removal of the amino-terminal functional group
abolishes the opioidergic activity of DYN 1–17 [47], with DYN 2–17 inactive at opioid recep-
tors [46, 48].
The inhibition of both IL-1β and TNF-α release by DYN 1–7 occurred in a reverse concen-
tration-dependent manner through interaction with KOP receptor which correlates with our
prior NF-κB/p65 translocation findings. It is interesting to note that U50,488H, a selective
KOP agonist, at 10 pM exhibited similar inhibitory effects to DYN 1–7 on the release of IL-1β
and TNF-α in differentiated THP-1 cells and correlates with the previous findings for NF-κB/
p65 translocation. Supporting this, a prior study has also reported the inhibitory effects of
U50,488H at concentrations as low as 0.1 nM on the release of IL-1β and TNF-α in macro-
phage cell line P388D1 upon binding on KOP receptor. This effect was similarly shown to be
mediated via the KOP receptor by reversal with norbinaltorphimine (nor-BNI), a kappa-selec-
tive antagonist [30].
The discrepancy between effects of DYN 1–17 and DYN 1–6 in comparison with DYN 1–7
on IL-1ß and TNF-α release suggest differential effects of KOP receptors on cytokine modula-
tion. Similarly, previous studies have reported different responses produced by ligands that are
active at the same receptor site [49]. The differential effects exhibited by KOP receptor agonists
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in mediating KOP receptor-mediated antinociception has been reported previously. At low
concentrations, a selective KOP receptor subtype 3 agonist, nalorphine, significantly blocked
morphine analgesia, however at a higher concentration, the agonist produced complete analge-
sia [50]. The KOP selective agonist U69,593 was found to elicit a higher analgesic response in
comparison to U50,488H (95% vs 60%) [51]. Furthermore, the differences in signalling mecha-
nisms of the KOP receptor agonists could be due to the opioid receptor heterodimerisation as
shown by the synergistic binding of highly selective agonists by kappa-delta receptor heterodi-
mers that further potentiates the signal transduction which are distinct from those of either
receptor [52].
In addition, despite of the common structural elements shared between the non-peptide
kappa selective ligands and the naturally occurring kappa opioid peptides, both classes showed
differential modulation on immune functions. This discrepancy is not clear; however several
possibilities may be suggested. Firstly, the complex structure with multiple stereocenters of the
non-peptide KOP receptor agonists in comparison with the kappa opioid peptides results in
differential regulation of the KOP receptor due to the different receptor conformational
changes induced by both classes of ligands [40, 53]. Secondly, both classes of ligand may have
a distinct regulation of calcium signalling in immune cells. Calcium signalling has been
denoted as one of the second messenger systems that play an important role in opioid-medi-
ated immune activation and regulation [54]. Supporting this, an earlier study has reported that
both dynorphin and U50, 488H regulate the intracellular calcium homeostasis differently in
guinea pig cerebellar synaptomes [55]. Finally, the kappa opioid peptides may have a tendency
to bind to other opioid receptors albeit with low affinity whereas the non-peptide kappa ligands
such as U50, 488H selectively bind to KOP receptor only [30], which defines the diverse
immune regulatory pathways. Taken together, all these possibilities may explain the diverse
immune regulatory pathways by both classes of KOP receptor ligands due to their distinct sen-
sitivities on KOP receptor in producing their biological effects in immune cells.
In conclusion, DYN 1–17 and select N-terminal fragments modulate the nuclear transloca-
tion of NF-κB/p65 protein and subsequent modulation of downstream pro-inflammatory cyto-
kine release. Based on structural-specificity relationship of the fragments, we suggest that N-
terminal fragments, comprising seven amino acids in the peptide sequence, are acting through
the KOP receptor—as demonstrated by DYN 1–7, that effectively inhibits NF-κB/p65 translo-
cation and downstream release of inflammatory IL-1β and TNF-α cytokines through KOP
receptor. It is plausible that the involvement of non-KOP receptor mechanisms mediate the
effects at different concentrations as well as for other N-terminal fragments in the regulation of
NF-κB/p65 signal and cytokine release in differentiated THP-1 cells, which warrants further
investigation.
Supporting Information
S1 Data. Numerical data used in preparation of Figs 2, 3, 5, 6A–6D and S1, S2, S3A and
S3B, S4A, S4B and S4C Figs.
(XLSX)
S1 Fig. The absence of NF-κB/p65 nuclear translocation by DYN 1–17 and the N-terminal
fragments in non-stimulated THP-1 cells. The non-stimulated THP-1 cells were treated with
the N-terminal fragments of DYN 1–17 and U50,488H at 1 μM and 10 nM for an hour. The
treated cells were fixed with paraformaldehyde (3.7%) and immunolabelled with primary anti-
NF-κB/p65 monoclonal antibody and visualized using Alexa Fluor 5551 secondary antibody.
DAPI staining was used to identify the nuclei. The nuclear translocation of NF-κB/p65 in each
treatment group was assessed using the Image Xpress screening system. Non-stimulated THP-
DYN 1-17, NF-kappa B, Interleukin-1beta and TNF-alpha
PLOS ONE | DOI:10.1371/journal.pone.0153005 April 7, 2016 14 / 18
1 cells (NS) served as negative control. The NF-κB/p65 translocation percentage in each treat-
ment group was normalised and expressed relative to LPS-stimulated control group. Data
shown are the means ± S.E.M. of at least three independent experiments performed in tripli-
cates.
(TIF)
S2 Fig. Cell viability of LPS-induced THP-1 cells following treatment with DYN 1–17 and
the N-terminal fragments. Cell viability of LPS-induced THP-1 cells was determined by the
MTT assay. Cells were exposed to the peptides for 24 hr and cells were treated with MTT and
incubated for a further 4 hr. The metabolite formazan was measured using a microplate reader.
Data shown are the means ± S.E.M. of at least three independent experiments performed in
triplicates.
(TIF)
S3 Fig. Effect of ML-190 and DMSO on the release of A. IL-1β and B. TNF-α in LPS-stimu-
lated THP-1 cells. The LPS-stimulated THP-1 cells were treated with ML-190 (10 μM) and
DMSO (0.1%) for 24 hr. The culture supernatants were collected and IL-1β and TNF-α release
was measured using IL-1β and TNF-α AlphaLISA kit, respectively. The AlphaLISA signal was
read using an Enspire-Alpha 2390 Multilabel Plate Reader. Non-stimulated THP-1 cells (NS)
served as negative control. The release of IL-1β and TNF-α in each treatment group was
normalised and expressed relative to LPS-stimulated control group. Data shown are the
means ± S.E.M. of at least three independent experiments performed in triplicates.
(TIF)
S4 Fig. Effect of DYN 1–9, DYN 1–10 and DYN 1–11 on the release of IL-1β and TNF-α in
LPS-stimulated THP-1 cells. The LPS-stimulated THP-1 cells were treated with DYN 1–9,
DYN 1–10 and DYN 1–11 at 0.1 μM, 1 nM and 10 pM for 24 hr. The culture supernatants
were collected and IL-1β and TNF-α release was measured using IL-1β and TNF-α AlphaLISA
kit, respectively. The AlphaLISA signal was read using an Enspire-Alpha 2390 Multilabel Plate
Reader. Non-stimulated THP-1 cells (NS) served as negative control. The release of IL-1β and
TNF-α in each treatment group was normalised and expressed relative to LPS-stimulated con-
trol group. Data shown are the means ± S.E.M. of at least three independent experiments per-
formed in triplicates.
(TIF)
Author Contributions
Conceived and designed the experiments: SF MM PG PNS PJC. Performed the experiments:
SF. Analyzed the data: SF MM PJC. Contributed reagents/materials/analysis tools: PJC. Wrote
the paper: SF MM PNS PJC.
References
1. Alt A, Mansour A, Akil H, Medzihradsky F, Traynor JR, Woods JH. Stimulation of guanosine-5'-O-(3-
[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J Pharmacol
Exp Ther. 1998; 286: 282–288. PMID: 9655870
2. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid
receptor. Science. 1982; 215: 413–415. PMID: 6120570
3. Zhang Q, Schaffer M, Elde R, Stein C. Effects of neurotoxins and hindpaw inflammation on opioid
receptor immunoreactivities in dorsal root ganglia. Neuroscience. 1998; 85: 281–291. PMID: 9607719
4. Safavi A, Hersh LB. Degradation of dynorphin-related peptides by the puromycin-sensitive aminopepti-
dase and aminopeptidase M. J Neurochem. 1995; 65: 389–395. PMID: 7790884
DYN 1-17, NF-kappa B, Interleukin-1beta and TNF-alpha
PLOS ONE | DOI:10.1371/journal.pone.0153005 April 7, 2016 15 / 18
5. Morgan M, Herath HM, Cabot PJ, Shaw PN, Hewavitharana AK. Dynorphin A 1–17 biotransformation
in inflamed tissue, serum and trypsin solution analysed by liquid chromatography-tandemmass spec-
trometry. Anal Bioanal Chem. 2012; 404: 3111–3121. doi: 10.1007/s00216-012-6406-8 PMID:
23001306
6. Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010; 1314: 56–73. doi: 10.
1016/j.brainres.2009.09.074 PMID: 19782055
7. Singh R, Rai U. Kappa-opioid receptor-mediated modulation of innate immune response by dynorphin
in teleostChanna punctatus. Peptides. 2010; 31: 973–978. doi: 10.1016/j.peptides.2010.01.009 PMID:
20132853
8. Foster JS, Moore RN. Dynorphin and related opioid peptides enhance tumoricidal activity mediated by
murine peritoneal macrophages. J Leukoc Biol. 1987; 42: 171–174. PMID: 2439627
9. Tosk JM, Grim JR, Kinback KM, Sale EJ, Bozzetti LP, Will AD. Modulation of chemiluminescence in a
murine macrophage cell line by neuroendocrine hormones. Int J Immunopharmacol. 1993; 15: 615–
620. PMID: 8104166
10. Prete P, Levin ER, Pedram A. The in vitro effects of endogenous opiates on natural killer cells, antigen-
specific cytolytic T cells, and T-cell subsets. Exp Neurol. 1986; 92: 349–359. PMID: 3485536
11. Welters ID, Menzebach A, Goumon Y, Cadet P, Menges T, Hughes TK, et al. Morphine inhibits NF-kap-
paB nuclear binding in human neutrophils and monocytes by a nitric oxide-dependent mechanism.
Anesthesiology. 2000; 92: 1677–1684. PMID: 10839919
12. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Dis-
cov. 2009; 8: 33–40. doi: 10.1038/nrd2781 PMID: 19116625
13. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol.
2009; 1: a001651. doi: 10.1101/cshperspect.a001651 PMID: 20457564
14. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002; 109 Suppl: S81–96. PMID:
11983155
15. Budd K, Shipton EA. Acute pain in the immune system and opioimmunosuppression. Acute Pain. 2004;
6: 123–135.
16. Roy S, Cain KJ, Chapin RB, Charboneau RG, Barke RA. Morphine modulates NF kappa B activation in
macrophages. Biochem Biophys Res Commun. 1998; 245: 392–396. PMID: 9571161
17. Borner C, Kraus J. Inhibition of NF-kappaB by opioids in T cells. J Immunol. 2013; 191: 4640–4647. doi:
10.4049/jimmunol.1300320 PMID: 24068670
18. Auwerx J. The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-mac-
rophage differentiation. Experientia. 1991; 47: 22–31. PMID: 1999239
19. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characteri-
zation of a human acute monocytic leukemia cell line (THP-1). Int J Cancer. 1980; 26: 171–176. PMID:
6970727
20. Tsuchiya S, Kobayashi Y, Goto Y, Okumura H, Nakae S, Konno T, et al. Induction of maturation in cul-
tured humanmonocytic leukemia cells by a phorbol diester. Cancer Res. 1982; 42: 1530–1536. PMID:
6949641
21. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye
method for measuring cell growth/cell kill. J Immunol Methods. 1989; 119: 203–210. PMID: 2470825
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and
cytotoxicity assays. J Immunol Methods. 1983; 65: 55–63. PMID: 6606682
23. Kanduri M, Tobin G, Åleskog A, Nilsson K, Rosenquist R. The novel NF-κB inhibitor IMD-0354 induces
apoptosis in chronic lymphocytic leukemia. Blood Cancer J. 2011; 1: e12. doi: 10.1038/bcj.2011.9
PMID: 22829125
24. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring
Harb Perspect Biol. 2009; 1: a000034. doi: 10.1101/cshperspect.a000034 PMID: 20066092
25. Schmitz ML, Baeuerle PA. The p65 subunit is responsible for the strong transcription activating poten-
tial of NF-kappa B. EMBO J. 1991; 10: 3805–3817. PMID: 1935902
26. Trask OJ Jr.. Nuclear factor kappa B (NF-κB) translocation assay development and validation for high
content screening Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Transla-
tional Sciences; 2012. Available from: http://www.ncbi.nlm.nih.gov/books/NBK100914/
27. Ichinose M, Asai M, SawadaM. Enhancement of phagocytosis by dynorphin A in mouse peritoneal
macrophages. J Neuroimmunol. 1995; 60: 37–43. PMID: 7642746
28. Chanput W, Mes J, Vreeburg RA, Savelkoul HF, Wichers HJ. Transcription profiles of LPS-stimulated
THP-1 monocytes and macrophages: a tool to study inflammation modulating effects of food-derived
compounds. Food Func. 2010; 1: 254–261.
DYN 1-17, NF-kappa B, Interleukin-1beta and TNF-alpha
PLOS ONE | DOI:10.1371/journal.pone.0153005 April 7, 2016 16 / 18
29. Kong LY, McMillian MK, Hudson PM, Jin L, Hong JS. Inhibition of lipopolysaccharide-induced nitric
oxide and cytokine production by ultralow concentrations of dynorphins in mixed glia cultures. J Phar-
macol Exp Ther. 1997; 280: 61–66. PMID: 8996182
30. Belkowski SM, Alicea C, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of interleukin-1 and tumor
necrosis factor-alpha synthesis following treatment of macrophages with the kappa opioid agonist U50,
488H. J Pharmacol Exp Ther. 1995; 273: 1491–1496. PMID: 7791124
31. Faden AI, Ellison JA, Noble LJ. Effects of competitive and non-competitive NMDA receptor antagonists
in spinal cord injury. Eur J Pharmacol. 1990; 175: 165–174. PMID: 2155794
32. Meyer ME. Intrastriatal injections of dynorphin A fragments potentiate the dorsal immobility response in
rats. Pharmacol Biochem Behav. 1993; 44: 329–332. PMID: 8095341
33. Ishihara S, Tsuchiya S, Horie S, Murayama T, Watanabe K. Gastric acid secretion by central injection
of dynorphin A-(1–17), an endogenous ligand of kappa-opioid receptor, in urethane-anesthetized rats.
Jpn J Pharmacol. 2001; 87: 14–20. PMID: 11676193
34. Kumar S, Rai U. Dynorphin regulates the phagocytic activity of splenic phagocytes in wall lizards:
involvement of a kappa-opioid receptor-coupled adenylate-cyclase-cAMP-PKA pathway. J Exp Biol.
2011; 214: 4217–4222. doi: 10.1242/jeb.062935 PMID: 22116765
35. Banerjee P, Chromy BA, Berry-Kravis E, Hammond D, Singh JK, Dawson G. Stable expression and
heterologous coupling of the kappa opioid receptor in cell lines of neural and nonneural origin. Life Sci.
1996; 58: 1277–1284. PMID: 8614281
36. Buchner RR, Vogen SM, FischerW, Thoman ML, Sanderson SD, Morgan EL. Anti-human kappa opioid
receptor antibodies: characterization of site-directed neutralizing antibodies specific for a peptide
kappa R(33–52) derived from the predicted amino terminal region of the human kappa receptor. J
Immunol. 1997; 158: 1670–1680. PMID: 9029103
37. Cabot PJ. Immune-derived opioids and peripheral antinociception. Clin Exp Pharmacol Physiol. 2001;
28: 230–232. PMID: 11236131
38. Hassan AH, Pzewlocki R, Herz A, Stein C. Dynorphin, a preferential ligand for kappa-opioid receptors,
is present in nerve fibers and immune cells within inflamed tissue of the rat. Neurosci Lett. 1992; 140:
85–88. PMID: 1357608
39. Radulovic J, Miljevic C, Djergovic D, Vujic V, Antic J, von Horsten S, et al. Opioid receptor-mediated
suppression of humoral immune response in vivo and in vitro: involvement of kappa opioid receptors. J
Neuroimmunol. 1995; 57: 55–62. PMID: 7706440
40. Frankowski KJ, Hedrick MP, Gosalia P, Li K, Shi S, Whipple D, et al. Discovery of Small Molecule
Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strat-
egy. ACS ChemNeurosci. 2012; 3: 221–236. PMID: 22737280
41. Hedrick MP, Gosalia P, Li K, Frankowski KJ, Shi S, Prisinzano TE, et al. Antagonist for the Kappa Opi-
oid Receptor. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD): National
Center for Biotechnology Information (US); 2010.
42. Guan L, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of T cell superantigen responses following
treatment with the kappa-opioid agonist U50,488H. J Neuroimmunol. 1997; 75: 163–168. PMID:
9143250
43. Morgan EL. Regulation of human B lymphocyte activation by opioid peptide hormones. Inhibition of IgG
production by opioid receptor class (mu-, kappa-, and delta-) selective agonists. J Neuroimmunol.
1996; 65: 21–30. PMID: 8642060
44. Szabo I, Rojavin M, Bussiere JL, Eisenstein TK, Adler MW, Rogers TJ. Suppression of peritoneal mac-
rophage phagocytosis of Candida albicans by opioids. J Pharmacol Exp Ther. 1993; 267: 703–706.
PMID: 8246144
45. Alicea C, Belkowski S, Eisenstein TK, Adler MW, Rogers TJ. Inhibition of primary murine macrophage
cytokine production in vitro following treatment with the kappa-opioid agonist U50,488H. J Neuroimmu-
nol. 1996; 64: 83–90. PMID: 8598393
46. Walker JS. Anti-inflammatory effects of opioids. Adv Exp Med Biol. 2003; 521: 148–160. PMID:
12617572
47. Chavkin C, Goldstein A. Specific receptor for the opioid peptide dynorphin: structure—activity relation-
ships. Proc Natl Acad Sci U S A. 1981; 78: 6543–6547. PMID: 6118865
48. Gabrilovac J, Cupic B, Zapletal E, Brozovic A. IFN-gamma up-regulates kappa opioid receptors (KOR)
on murine macrophage cell line J774. J Neuroimmunol. 2012; 245: 56–65. doi: 10.1016/j.jneuroim.
2012.02.006 PMID: 22424981
49. Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact? Brit J Anaesth. 2011;
107: 8–18. doi: 10.1093/bja/aer115 PMID: 21613279
DYN 1-17, NF-kappa B, Interleukin-1beta and TNF-alpha
PLOS ONE | DOI:10.1371/journal.pone.0153005 April 7, 2016 17 / 18
50. Paul D, Pick CG, Tive LA, Pasternak GW. Pharmacological characterization of nalorphine, a kappa 3
analgesic. J Pharmacol Exp Ther. 1991; 257: 1–7. PMID: 1850462
51. Smith MA, French AM. Age-related differences in sensitivity to the antinociceptive effects of kappa opi-
oids in adult male rats. Psychopharmacology (Berl). 2002; 162: 255–264.
52. Jordan BA, Devi LA. G-protein-coupled receptor heterodimerization modulates receptor function.
Nature. 1999; 399: 697–700. PMID: 10385123
53. Li JG, Zhang F, Jin XL, Liu-Chen LY. Differential regulation of the human kappa opioid receptor by ago-
nists: etorphine and levorphanol reduced dynorphin A- and U50,488H-induced internalization and
phosphorylation. J Pharmacol Exp Ther. 2003; 305: 531–540. PMID: 12606694
54. Borner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B, et al. Mechanisms of opioid-medi-
ated inhibition of human T cell receptor signaling. J Immunol. 2009; 183: 882–889. doi: 10.4049/
jimmunol.0802763 PMID: 19561113
55. Olson KG, Welch SP. The effects of dynorphin A (1–13) and U50, 488H on free intracellular calcium in
guinea pig cerebellar synaptosomes. Life Sci. 1991; 48: 575–581. PMID: 1671526
DYN 1-17, NF-kappa B, Interleukin-1beta and TNF-alpha
PLOS ONE | DOI:10.1371/journal.pone.0153005 April 7, 2016 18 / 18
